2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.14 Long-Term Prognosis of Patients Undergoing Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer

EP.08D.14 Long-Term Prognosis of Patients Undergoing Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer

Back to course

Pdf Summary

This study examines the long-term prognosis of patients with locally advanced non-small-cell lung cancer (NSCLC) who underwent trimodality therapy, which includes induction chemoradiotherapy followed by surgery. Conducted at Okayama University Hospital from January 1999 to December 2021, it is a single-center, retrospective analysis involving 205 patients.<br /><br />The main findings indicate that trimodality therapy is a viable therapeutic option in terms of long-term prognosis for patients with this type of cancer. Among the 205 patients examined, certain factors were associated with better prognoses. These include a history of non-malignant comorbid diseases, non-lower lobe tumor locations, achieving a pathological complete response (pCR), avoiding post-operative complications like pneumonia and bronchopleural fistula, and not requiring re-operations. Notably, patients who received adjuvant therapy after surgery also fared better in the long run.<br /><br />Statistical analyses, including univariate (UA) and multivariate (MA), identified significant prognostic factors. For instance, the presence of pre-existing malignant diseases decreased median survival time (MST) significantly. Meanwhile, achieving a pCR was correlated with a significantly longer MST. Similarly, patients without post-operative pneumonia or the need for re-operation exhibited notably improved survival rates.<br /><br />Survival curves demonstrated a 5-year overall survival rate of 68.2% and a 10-year survival rate of 51.8% for all studied patients. For those without recurrence, 5-year and 10-year survival rates were 84.1% and 71.1%, respectively.<br /><br />The study concludes that trimodality therapy is a feasible treatment option and highlights the importance of patient-specific factors in determining long-term outcomes. The analysis underlines the importance of minimizing complications and highlights potential areas for improving survival rates in those suffering from locally advanced NSCLC.

Asset Subtitle

Kazuhiro Okada

Meta Tag

Speaker Kazuhiro Okada

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

NSCLC

trimodality therapy

induction chemoradiotherapy

surgery

pathological complete response

prognostic factors

long-term survival

post-operative complications

adjuvant therapy

survival rates